Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN R WEBSTER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1124129671
CMS profile
187421
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$344.12

25 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $344.12 25

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN R WEBSTER

NPI 1124129671 · CMS profile ID 187421

Allopathic & Osteopathic Physicians / Internal Medicine

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

25 matching records · $344.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 25 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–25 of 25.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $14.0811/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720467485 CMS
Novo Nordisk Inc $5.7109/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744899649 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.7909/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720467489 CMS
Novo Nordisk Inc $25.0008/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744841789 CMS
Novo Nordisk Inc $12.0408/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744814309 CMS
IRONWOOD PHARMACEUTICALS, INC $11.8607/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749817371 CMS
Novo Nordisk Inc $6.2106/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744757523 CMS
Novo Nordisk Inc $16.2305/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744693681 CMS
Kowa Pharmaceuticals America, Inc. $13.8503/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716723711 CMS
Lilly USA, LLC $13.8403/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728356859 CMS
SANOFI-AVENTIS U.S. LLC $11.5103/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744156151 CMS
Dynavax Technologies Corporation $18.1403/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747407237 CMS
Lilly USA, LLC $11.6002/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728356857 CMS
Amgen Inc. $12.9702/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740942163 CMS
Janssen Pharmaceuticals, Inc $11.5802/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719062941 CMS
Novo Nordisk Inc $17.3102/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744730465 CMS
Novo Nordisk Inc $14.2502/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744596247 CMS
BIODELIVERY SCIENCES INTERNATIONAL, INC. $13.0102/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747893453 CMS
GlaxoSmithKline, LLC. $12.5902/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738645835 CMS
Arbor Pharmaceuticals, Inc. $14.8502/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735747095 CMS
Amgen Inc. $14.6501/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740942161 CMS
Lilly USA, LLC $12.6501/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728370465 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.4201/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720467493 CMS
Novo Nordisk Inc $12.9801/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744555867 CMS
PFIZER INC. $12.0001/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743661937 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,614.26 105
PY2020 $344.12 25
PY2021 $166.49 11
PY2022 $147.76 12
PY2023 $45.48 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,179,650.03 45
PY2024 Principal investigator $1,336,794.36 51
PY2023 Recipient $628.25 1
PY2023 Principal investigator $421,175.77 35
PY2022 Principal investigator $414,800.07 178
PY2021 Principal investigator $249,631.83 98
PY2020 Principal investigator $39,638.70 30
PY2019 Principal investigator $10,918.41 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

98 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417195
Principal investigator 1 Esperion Therapeutics, Inc. $239.00 12/17/2021 Non-covered Recipient Entity
WILMINGTON HEALTH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838455969
Principal investigator 1 GlaxoSmithKline, LLC. $1,395.90 12/15/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809493373
Principal investigator 1 PFIZER INC. $4,274.11 12/07/2021 Non-covered Recipient Entity
Innovo Research Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832557437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417165
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417169
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417175
Principal investigator 1 PFIZER INC. $7,394.29 11/30/2021 Non-covered Recipient Entity
Innovo Research Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832668759
Principal investigator 1 GlaxoSmithKline, LLC. $787.50 11/24/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809493375
Principal investigator 1 GlaxoSmithKline, LLC. $2,015.10 11/17/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809493347
Principal investigator 1 GlaxoSmithKline, LLC. $945.00 11/01/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809499107
Principal investigator 1 GlaxoSmithKline, LLC. $1,091.70 11/01/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809518007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417139
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417145
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417153
Principal investigator 1 PFIZER INC. $1,269.00 10/29/2021 Non-covered Recipient Entity
Innovo Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832832317
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 10/26/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417113
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 10/26/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 10/24/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 10/24/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 10/24/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $70.00 10/24/2021 Non-covered Recipient Entity
Wilmington Health
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828417111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 10/24/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 10/24/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1.40 10/24/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 10/24/2021 Non-covered Recipient Entity
Wilmington Health
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417155
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 10/20/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809518043
Principal investigator 1 Janssen Research & Development, LLC $38.00 10/18/2021 Non-covered Recipient Entity
Wilmington Hlth Pllc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787847805
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/18/2021 Non-covered Recipient Entity
Wilmington Hlth Pllc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787847817
Principal investigator 1 Janssen Research & Development, LLC $387.00 10/18/2021 Non-covered Recipient Entity
Wilmington Hlth Pllc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787847829
Principal investigator 1 Janssen Research & Development, LLC $869.00 10/18/2021 Non-covered Recipient Entity
Wilmington Hlth Pllc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787847839
Principal investigator 1 GlaxoSmithKline, LLC. $1,417.50 10/13/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809499101
Principal investigator 1 GlaxoSmithKline, LLC. $1,102.50 10/06/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809518013
Principal investigator 1 PFIZER INC. $1,123.20 10/05/2021 Non-covered Recipient Entity
Innovo Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832765999
Principal investigator 1 PFIZER INC. $14,000.00 10/01/2021 Non-covered Recipient Entity
Innovo Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832809261
Principal investigator 1 PFIZER INC. $4,747.28 10/01/2021 Non-covered Recipient Entity
Innovo Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832841675
Principal investigator 1 PFIZER INC. $14,000.00 09/21/2021 Non-covered Recipient Entity
Innovo Research Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832668751
Principal investigator 1 PFIZER INC. $14,000.00 09/21/2021 Non-covered Recipient Entity
Innovo Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832761600
Principal investigator 1 PFIZER INC. $920.00 09/17/2021 Non-covered Recipient Entity
INNOVO RESEARCH WILMINGTON HEALTH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832578341
Principal investigator 1 PFIZER INC. $113.80 09/17/2021 Non-covered Recipient Entity
INNOVO RESEARCH WILMINGTON HEALTH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832578349
Principal investigator 1 PFIZER INC. $917.00 08/11/2021 Non-covered Recipient Entity
INNOVO RESEARCH WILMINGTON HEALTH
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832860957
Principal investigator 1 GlaxoSmithKline, LLC. $945.00 08/10/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809485123
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 08/10/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809511889
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 08/10/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809512017
Principal investigator 1 GlaxoSmithKline, LLC. $787.50 08/03/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809511895
Principal investigator 1 GlaxoSmithKline, LLC. $1,575.00 07/14/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809485127
Principal investigator 1 GlaxoSmithKline, LLC. $787.50 07/14/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809485129
Principal investigator 1 Janssen Research & Development, LLC $19.00 06/25/2021 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787746218
Principal investigator 1 GlaxoSmithKline, LLC. $1,260.00 06/23/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809485657
Principal investigator 1 GlaxoSmithKline, LLC. $1,260.00 06/09/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809511877
Principal investigator 1 Janssen Research & Development, LLC $16,388.00 05/25/2021 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787746205
Principal investigator 1 Janssen Research & Development, LLC $15,204.00 05/24/2021 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787746183
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 05/19/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809485663
Principal investigator 1 GlaxoSmithKline, LLC. $1,417.50 05/12/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809485627
Principal investigator 1 GlaxoSmithKline, LLC. $787.50 05/05/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809511883
Principal investigator 1 Janssen Research & Development, LLC $23,733.00 04/27/2021 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787746162
Principal investigator 1 GlaxoSmithKline, LLC. $945.00 04/21/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809485125
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 04/21/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809485665
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 04/07/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809485659
Principal investigator 1 GlaxoSmithKline, LLC. $787.50 04/07/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809491633
Principal investigator 1 GlaxoSmithKline, LLC. $787.50 04/01/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809485121
Principal investigator 1 Janssen Research & Development, LLC $13,526.00 03/24/2021 Non-covered Recipient Entity
Qcare Site Svcs Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787746023
Principal investigator 1 GlaxoSmithKline, LLC. $1,890.00 03/17/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809491629
Principal investigator 1 GlaxoSmithKline, LLC. $630.00 03/17/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809511865
Principal investigator 1 GlaxoSmithKline, LLC. $787.50 02/23/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809511871
Principal investigator 1 AstraZeneca UK Limited $83,347.05 02/22/2021 Non-covered Recipient Entity
WILMINGTON HEALTH
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 No dispute reported 06/30/2026 826472293
Principal investigator 1 GlaxoSmithKline, LLC. $945.00 02/17/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809485661
Principal investigator 1 GlaxoSmithKline, LLC. $1,575.00 02/03/2021 Non-covered Recipient Entity
PMG RESEARCH INC
Not supplied No dispute reported 06/30/2026 809491631
Principal investigator 1 GlaxoSmithKline, LLC. $945.00 01/04/2021 Non-covered Recipient Entity
PMG RESEARCH INC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 860871395